LH
Labcorp Holdings Inc.258.11
-5.22-1.98%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A explains Q4 volume dip, guidance color
Q&A brushed off Q4 Diagnostics organic volume at 1.1% as one-off noise from a troubled consumer genetics client and weather—adjusted, it tracked full-year strength. Management split 2026 Diagnostics growth evenly between volume and price/mix, baking in 30bp ACA hit and January weather. With PAMA delayed, they'll reinvest $25M-$30M contingency savings into growth while pushing RESULTS Act. Early development flat post-$50M streamlining, but margins expand; hospital pipeline stays robust. Esoteric mix hit 41.5%. Answers largely reaffirmed scripted momentum. Q4 dip? Pure anomaly.
Key Stats
Market Cap
21.45BP/E (TTM)
25.30Basic EPS (TTM)
10.20Dividend Yield
0.01%Recent Filings
8-K
Labcorp closes $750M term loan
10-K
FY2025 results
Labcorp Holdings posted FY2025 revenues of $13.95B, up 7.2% y/y with Dx at $10.88B (7.2% growth, 4.1% organic) and BLS $3.10B (6.0% growth, 4.0% organic), fueled by volume gains and acquisitions like Invitae. Dx margins expanded 50bps to 16.4%, BLS 40bps to 16.1% on efficiencies despite ED restructuring hitting $127M. Q4 accelerated organic momentum while capex hit $435M (3.1% of sales). Buybacks claimed $450M, dividends $241M. Debt stands at $5.2B. PAMA cuts loom for 2027.
8-K
Labcorp's strong 2025 results
Labcorp posted 2025 revenue of $13.95B, up 7.2% from 2024, with adjusted EPS climbing to $16.44 from $14.57 amid Diagnostics and Central Labs strength. Acquisitions totaled $582M; 130+ new tests launched, including FDA-cleared Alzheimer's blood test. Momentum strong. Guides 2026 revenue to $14.61B-$14.79B, adjusted EPS $17.55-$18.25.
8-K
Labcorp adds med expert to board
Labcorp appointed John H. Sampson, M.D., Ph.D., to its Board effective February 9, 2026, assigning him to the Quality and Compliance Committee. The neurosurgeon and dean of University of Colorado Anschutz School of Medicine brings expertise in oncology, neuroscience, and personalized medicine aligning with Labcorp's diagnostics and drug development strategy. His addition bolsters clinical and research leadership. Compensation follows the standard director program.
IPO
Website
Employees
Sector
Industry
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
GH
Guardant Health, Inc.
100.00-2.67
IDXX
IDEXX Laboratories, Inc.
693.18-6.95
IQV
IQVIA Holdings, Inc.
221.68-1.95
MEDP
Medpace Holdings, Inc.
558.74-0.39
MEHCQ
CHROME HLDG CO
3.50+0.00
OPK
Opko Health, Inc.
1.31-0.04
TMO
Thermo Fisher Scientific Inc
570.16-5.75